The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML).
 
Victoria Wang
Stock and Other Ownership Interests - Abbott; Abbvie; Amgen; Blueprint Medicines; Gilead Sciences (I); Kura Oncology
 
Gabriel N. Mannis
Consulting or Advisory Role - Amgen
Research Funding - Agios (Inst); Juno Therapeutics (Inst)
 
Rebecca Leah Olin
Research Funding - Clovis Oncology (I); Daiichi Sankyo
 
Aaron Logan
Consulting or Advisory Role - Amgen; Pharmacyclics
Research Funding - Astellas Pharma; Novartis; Pharmacyclics
 
Thomas G. Martin
Research Funding - AMGEN (Inst); Sanofi (Inst)
 
Lloyd Earl Damon
Honoraria - Gilead Sciences (I); Pulmonary Hypertension Association (I)
Consulting or Advisory Role - Actelion (I); Amgen (I); Harvard Clinical Research Institute (I); Janssen (I); Otsuka (I); St. Jude Medical (I); Theranova (I)
Research Funding - Sigma-Tau; Sunesis Pharmaceuticals
 
Danielle Kilayko
No Relationships to Disclose
 
Pamela N. Munster
Stock and Other Ownership Interests - OncoSec (I)
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)
 
Charalambos Andreadis
Employment - Genentech (I)
Stock and Other Ownership Interests - Roche/Genentech (I)
Consulting or Advisory Role - Gilead Sciences; Millennium; Pfizer; Pharmacyclics; Seagen; Spectrum Pharmaceuticals
Research Funding - Amgen; Cellerant; GlaxoSmithKline; Karyopharm Therapeutics; Novartis